A hormone treatment called tesamorelin slightly raises long-term blood sugar levels by 0.19% more than a placebo in people with HIV after six months of treatment.
Scientific Claim
Tesamorelin leads to a modest increase in HbA1c by 0.19% compared to placebo over 6 months in HIV-infected adults.
Original Statement
“a modest increase in HbA1c from baseline to 6 months (Δ 0.20 [0.04, 0.36] vs. 0.02 [−0.07, 0.10] %, mean [95% CI], treatment effect 0.19% [95% CI 0.01, 0.36], P = 0.03).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
As a randomized controlled trial, this study design supports causal language for this secondary outcome. The verb 'leads to' is appropriate for the observed effect.
Evidence from Studies
Supporting (1)
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.